Clinical Trial

Intranasal Dexmedetomidine and Perioperative Myocardial Injury

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
PCI is the standard treatment for CAD, yet perioperative myocardial injury occurs frequently in nearly 40% of patients. Perioperative stress and sympathetic overactivation break myocardial oxygen balance and lead to cardiac damage, which further raises short-term cardiovascular events and long-term mortality risks. Dexmedetomidine exerts cardioprotective effects by inhibiting sympathetic excitation, though intravenous use carries risks of hypotension and bradycardia. Intranasal dexmedetomidine shows equivalent efficacy with fewer side effects and better patient compliance. Since no standard perioperative anesthesia regimen exists for elective PCI patients and the clinical benefits of dexmedetomidine remain unconfirmed, this pilot study is designed to test the feasibility and safety of intranasal dexmedetomidine spray before launching large formal RCTs.
Protocol Amendment History 5 changes
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
critical Primary endpoint(s) modified 2026-07-31
notable Enrollment reduced: 1800 -> 140 participants 2026-07-31
notable Primary completion moved earlier: 2028-01 -> 2027-01 2026-07-31
minor Completion moved earlier: 2028-04 -> 2027-02 2026-07-31
Trial Details
NCT Number NCT07549282
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Coronary Heart Disease, Myocardial Injury, Myocardial Infarction, Dexmedetomidine
Enrollment 140 participants
Start Date 2026-08
Primary Completion 2027-01 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-30